Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT06743945

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Led by Fudan University · Updated on 2025-02-25

20

Participants Needed

1

Research Sites

249 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.

CONDITIONS

Official Title

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 80 years old
  • Histologically confirmed transformed diffuse large B-cell lymphoma (DLBCL)
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Signed informed consent form
  • Adequate organ function including hematopoietic, liver, renal function, and heart function (left ventricular ejection fraction ≥ 50%)
Not Eligible

You will not qualify if you...

  • Allergy or sensitivity to human or mouse monoclonal antibodies or murine products
  • Previous organ transplantation
  • Prior treatment with cytotoxic drugs within 5 years or prior use of anti-CD20 antibodies
  • Uncontrolled significant cardiovascular or pulmonary diseases
  • Major surgery within 4 weeks before enrollment (except diagnostic surgery)
  • Active infections or recent major infections within 2 weeks before treatment start
  • Previous radiotherapy in the mediastinum or pericardial region
  • Active chronic hepatitis B infection or positive HBV DNA without proper management
  • Positive hepatitis C antibody with detectable HCV RNA
  • Active HIV or syphilis infections
  • Pregnant or lactating women
  • Investigator’s judgment deeming the patient unsuitable for participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China, 200032

Actively Recruiting

Loading map...

Research Team

Y

Yizhen Liu, M.D., Ph.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here